Results 81 to 90 of about 867,834 (298)

Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) [Corrigendum]

Cancer Management and Research, 2019
Casadei-Gardini A, Montagnani F, Casadei C, et al. Cancer Manag Res. 2019;11:3631–3642. The authors have advised that the affiliations are not correct in the published paper (page 3631).
Casadei-Gardini A, Montagnani F, Casadei C, Arcadipane F, Andrikou K, Aloi D, Prete AA, Zampino MG, Argentiero A, Pugliese G, Martini S, Iorio GC, Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Marisi G, Dell'Acqua V, Ravenda PS, Lonardi S, Silvestris N, De Bari B, Ricardi U, Cascinu S, Franco P   +24 more
doaj  

Anaplastic Thyroid Carcinoma versus Metastatic SCC: A Diagnostic Dilemma in a Rare Presentation of Post-Radiation Thyroid Swelling

Indian Journal of Medical and Paediatric Oncology
A 71-year-old male with type 2 diabetes and hypertension was diagnosed with carcinoma of the pyriform fossa in 2019. The biopsy was reported as a moderately differentiated squamous cell carcinoma, and positron emission tomography-computed tomography (PET-
Vrushab Rao, Bhooshan Zade
doaj   +1 more source

Medical and Neuro-Oncology [PDF]

Neuro-Oncology, 2010
G. K. Prithviraj, S. R. Sommers, R. L. Jump, B. Halmos, L. B. Chambless, S. L. Parker, L. Hassam-Malani, M. J. McGirt, R. C. Thompson, L. B. Chambless, S. L. Parker, L. Hassam-Malani, M. J. McGirt, R. C. Thompson, K. Hunter, M. C. Chamberlain, E. M. Le, E. L. T. Lee, M. C. Chamberlain, Z. S. Sadighi, M. L. Pearlman, J. M. Slopis, T. S. Vats, S. Khatua, N. C. DeVito, M. Yu, R. Chen, E. Pan, T. Cloughesy, J. Raizer, J. Drappatz, M. Gerena-Lewis, J. Rogerio, S. Yacoub, A. Desjardin, M. D. Groves, J. DeGroot, M. Loghin, C. A. Conrad, K. Hess, J. Ni, S. Ictech, K. Hunter, W. A. Yung, A. B. Porter, A. C. Dueck, N. J. Karlin, M. C. Chamberlain, J. Olson, J. Silber, A. S. Reiner, K. S. Panageas, F. M. Iwamoto, T. F. Cloughesy, K. D. Aldape, A. L. Rivera, A. F. Eichler, D. N. Louis, N. A. Paleologos, B. J. Fisher, L. S. Ashby, J. G. Cairncross, G. B. Roldan, P. Y. Wen, K. L. Ligon, D. Shiff, H. I. Robins, B. G. Rocque, M. C. Chamberlain, W. P. Mason, S. A. Weaver, R. M. Green, F. G. Kamar, L. E. Abrey, L. M. DeAngelis, S. C. Jhanwar, M. K. Rosenblum, A. B. Lassman, D. Cachia, L. Alderson, R. Moser, T. Smith, S. Yunus, K. Saito, A. Mukasa, Y. Narita, Y. Tabei, N. Shinoura, S. Shibui, N. Saito, B. Flechl, M. Ackerl, C. Sax, K. Dieckmann, R. Crevenna, G. Widhalm, M. Preusser, C. Marosi, C. Marosi, C. Ay, M. Preusser, D. Dunkler, G. Widhalm, I. Pabinger, K. Dieckmann, C. Zielinski, M. Belongia, S. Jogal, K.-H. Schlingensiepen, U. Bogdahn, G. Stockhammer, A. K. Mahapatra, N. K. Venkataramana, V. Oliushine, V. Parfenov, I. Poverennova, P. Hau, P. Jachimczak, H. Heinrichs, A. G. Mammoser, N. A. Shonka, J. F. de Groot, I. Shibahara, Y. Sonoda, T. Kumabe, R. Saito, M. Kanamori, Y. Yamashita, M. Watanabe, C. Ishioka, T. Tominaga, A. Silvani, P. Gaviani, E. Lamperti, A. Botturi, F. DiMeco, G. Broggi, L. Fariselli, C. L. Solero, A. Salmaggi, R. M. Green, E. A. Woyshner, T. F. Cloughesy, F. Shu, Y. S. Oh, S. Iganej, G. Singh, S. L. Vemuri, B. J. Theeler, B. Ellezam, M. R. Gilbert, T. Aoki, H. Kobayashi, S. Takano, R. Nishikawa, N. Shinoura, M. Nagane, Y. Narita, Y. Muragaki, K. Sugiyama, J. Kuratsu, M. Matsutani, Z. S. Sadighi, S. Khatua, L. A. Langford, V. K. Puduvalli, D. Shen, Z.-p. Chen, J.-p. Zhang, Z.-p. Chen, D. Bedekar, S. Rand, J. Connelly, M. Malkin, E. Paulson, W. Mueller, K. Schmainda, O. Gallego, M. Benavides, P. P. Segura, C. Balana, M. Gil, A. Berrocal, G. Reynes, J. L. Garcia, P. Murata, S. Bague, M. J. Quintana, V. G. Vasishta, M. Nagane, K. Kobayashi, M. Tanaka, K. Tsuchiya, Y. Shiokawa, A. A. Bavle, K. Ayyanar, V. K. Puduvalli, M. P. Prado, K. R. Hess, K. Hunter, D. Bota   +200 more
openaire   +2 more sources

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source

Information Needed to Conduct First-in-Human Oncology Trials in the United States: A View from a Former FDA Medical Reviewer [PDF]

, 2010
Adrian M. Senderowicz
openalex   +1 more source

Screening for lung cancer: A systematic review of overdiagnosis and its implications

Molecular Oncology, EarlyView.
Low‐dose computed tomography (CT) screening for lung cancer may increase overdiagnosis compared to no screening, though the risk is likely low versus chest X‐ray. Our review of 8 trials (84 660 participants) shows added costs. Further research with strict adherence to modern nodule management strategies may help determine the extent to which ...
Fiorella Karina Fernández‐Sáenz, Laura de la Torre‐Perez, David R Baldwin, Carlijn van der Aalst, Mangesh Thorat, David Ritchie, Andre L Carvalho, Carolina Espina, Ivan Solà, Carlos Canelo‐Aybar, Moira Magdalena Pissinis, Pablo Alonso‐Coello, Ana Carolina Pereira Nunes Pinto   +12 more
wiley   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Survivin and Aurora Kinase A control cell fate decisions during mitosis

Molecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir, Shalitha Wickrama Arachchige, Sally P. Wheatley   +2 more
wiley   +1 more source

Guidelines for the diagnosis and treatment of basal cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology [PDF]

, 2023
Paola Queirolo, Michela Cinquini, Giuseppe Argenziano, Franco Bassetto, Paolo Bossi, Andrea Boutros, Claudio Clemente, Vincenzo De Giorgi, Michele Del Vecchio, Roberto Patuzzo, Ketty Peris, Pietro Quaglino, Alessia Reali, Iris Zalaudek, Francesco Spagnolo   +14 more
openalex   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source